Showing results (1-10 of 21) with videos related to
Sort By:
Pageof 3
Molecular Pharmaceutics|February 3, 2025
New Trends in Brain Shuttle PeptidesRoger Prades, Meritxell Teixidó, Benjamí Oller-SalviaJournal of Medicinal Chemistry|February 23, 2010
N-methyl phenylalanine-rich peptides as highly versatile blood-brain barrier shuttlesMorteza Malakoutikhah, Roger Prades, Meritxell Teixidó, et al.Molecular Pharmacology|October 1, 2010
Rational design of a selective covalent modifier of G protein βγ subunitsAxel L Dessal, Roger Prades, Ernest Giralt, et al.Future Medicinal Chemistry|September 13, 2013
Peptide POP inhibitors for the treatment of the cognitive symptoms of schizophreniaAbraham López, Laura Mendieta, Roger Prades, et al.Bioorganic & Medicinal Chemistry|July 25, 2008
Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitorTeresa Tarragó, Nessim Kichik, Birgit Claasen, et al.Scientific Reports|March 21, 2019
A MALDI-TOF-based Method for Studying the Transport of BBB Shuttles-Enhancing Sensitivity and Versatility of Cell-Based In Vitro Transport ModelsPol Arranz-Gibert, Bernat Guixer, Roger Prades, et al.Schizophrenia Research|May 9, 2016
The glial phosphorylase of glycogen isoform is reduced in the dorsolateral prefrontal cortex in chronic schizophreniaRaquel Pinacho, Elia Vila, Roger Prades, et al.Biopolymers|July 30, 2013
Dual system for the central nervous system targeting and blood-brain barrier transport of a selective prolyl oligopeptidase inhibitorMeritxell Teixidó, Esther Zurita, Laura Mendieta, et al.Bioorganic Chemistry|November 3, 2019
Design and synthesis of selective and blood-brain barrier-permeable hydroxamate-based gelatinase inhibitorsAlexandra Bertran, Danylo Khomiak, Anna Konopka, et al.Journal of Psychiatric Research|September 2, 2014
Increased SP4 and SP1 transcription factor expression in the postmortem hippocampus of chronic schizophreniaRaquel Pinacho, Elsa M Valdizán, Fuencisla Pilar-Cuellar, et al.Pageof 3